Table of Content

1. Key Insights

2. Report Introduction

3. Glaucoma Market Overview at a Glance
3.1. Market Share (%) Distribution of Glaucoma by class in the 7MM in 2019
3.2. Market Share (%) Distribution of Glaucoma by class in the 7MM in 2032

4. Executive Summary of Glaucoma
4.1. Treatment landscape of Glaucoma

5. Disease Background and Overview
5.1. Introduction
5.2. Classification of Glaucoma
5.2.1. Classification of Open-Angle Glaucoma (OAG)
5.2.1.1. Primary Open-Angle Glaucoma (POAG)
5.2.1.2. Secondary Open-Angle Glaucoma
5.2.2. Classification of Close-Angle Glaucoma/Angle-closure glaucoma (ACG)
5.3. Signs and Symptoms of Glaucoma
5.3.1. Signs and Symptoms of Open-Angle Glaucoma
5.3.2. Signs and Symptoms of Closed-angle Glaucoma
5.4. Genes Involved in Glaucoma
5.4.1. Primary Open Angle Glaucoma
5.4.2. Primary Closed Angle Glaucoma (PACG)
5.5. Diagnosis
5.5.1. Diagnosis of Glaucoma
5.5.2. Diagnostic criteria of Angle Closure Glaucoma
5.5.3. Differential Diagnosis of Glaucoma
5.5.4. Diagnostic Algorithm for Glaucoma
5.5.5. Diagnosis of Juvenile Open Angle Glaucoma (JOAG)
5.5.6. Diagnosis of Steroid Induced Glaucoma (SIG)
5.5.7. Primary Glaucoma Preferred Practice Pattern guidelines
5.6. Treatment Algorithm of Glaucoma
5.7. Treatment and Management of Glaucoma
5.7.1. Medicines
5.7.2. Laser treatment
5.7.3. Surgery
5.7.4. Treatment of Primary Open-angle Glaucoma
5.7.5. Treatment for Angle-closure glaucoma (ACG)
5.7.6. Treatment for Juvenile Open Angle Glaucoma (JOAG)
5.7.7. Treatment for Steroid Induced Glaucoma (SIG)
5.8. Treatment and Management Guidelines of Glaucoma
5.8.1. International Council of Ophthalmology Guidelines for Glaucoma Eye Care
5.8.2. Level of evidence and recommendation in medical treatment of PACG.
5.8.3. European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation
5.8.4. Primary Open-angle Glaucoma Preferred Practice Pattern guidelines

6. Epidemiology and Patient Population
6.1. Key Findings
6.2. Epidemiology Methodology
6.3. Total Diagnosed Prevalence of Glaucoma in the 7MM
6.4. Assumptions and Rationales: 7MM
6.5. The United States
6.5.1. Total Diagnosed Prevalence of Glaucoma in the United States
6.5.2. Type-specific Diagnosed Prevalence of Glaucoma in the United States
6.5.3. Type-specific Diagnosed Prevalence of Open-Angle Glaucoma (OAG) in the United States
6.5.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States
6.5.5. Gender-specific Diagnosed Prevalence of Glaucoma in the United States
6.5.6. Age-specific Diagnosed Prevalence of Glaucoma in the United States
6.6. EU5
6.6.1. Total Diagnosed Prevalence of Glaucoma in the EU-5
6.6.2. Type-specific Diagnosed Prevalence of Glaucoma in EU-5
6.6.3. Type-specific Diagnosed Prevalence of Open angle Glaucoma in EU-5
6.6.4. Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5
6.6.5. Gender-specific Diagnosed Prevalence of Glaucoma in EU-5
6.6.6. Age-specific Diagnosed Prevalence of Glaucoma in EU-5
6.7. Japan
6.7.1. Total Diagnosed Prevalence of Glaucoma in Japan
6.7.2. Type-specific Diagnosed Prevalence of Glaucoma in Japan
6.7.3. Type-Specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan
6.7.4. Type-Specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in Japan
6.7.5. Gender-specific Diagnosed Prevalence of Glaucoma in Japan
6.7.6. Age-specific Diagnosed Prevalence of Glaucoma in Japan

7. Patient Journey

8. Marketed Products
8.1. Key Cross
8.2. Durysta (Bimatoprost SR): Allergan
8.2.1. Product Description
8.2.2. Regulatory Milestones
8.2.3. Clinical Development
8.2.4. Clinical Trials Information
8.2.5. Safety and Efficacy
8.2.6. Product Profile
8.3. Xelpros (latanoprost ophthalmic emulsion) 0.005%: Sun Pharma Advanced Research Company Limited
8.3.1. Product Description
8.3.2. Regulatory Milestones
8.3.3. Clinical Development
8.3.4. Safety and Efficacy
8.3.5. Product Profile
8.4. Tapcom/DE-111 (Tafluprost/timolol maleate): Santen Pharmaceutical Co., Ltd.
8.4.1. Product Description
8.4.2. Regulatory Milestones
8.4.3. Clinical Development
8.4.4. Clinical Trials Information
8.4.5. Safety and Efficacy
8.4.6. Product Profile
8.5. Glanatec: D.Western Therapeutics Institute (DWTI)/Kowa Ltd.
8.5.1. Product Description
8.5.2. Regulatory Milestones
8.5.3. Clinical Development
8.5.4. Clinical Trials Information
8.5.5. Safety and Efficacy
8.5.6. Product Profile
8.6. Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%: Alcon
8.6.1. Product Description
8.6.2. Regulatory Milestones
8.6.3. Clinical Development
8.6.4. Clinical Trials Information
8.6.5. Safety and Efficacy
8.6.6. Product Profile
8.7. AILAMIDE/ SJP-0125: Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
8.7.1. Product Description
8.7.2. Regulatory Milestones
8.7.3. Clinical Development
8.7.4. Product Profile
8.8. Aibeta/SJP-0135: Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd.
8.8.1. Product Description
8.8.2. Regulatory Milestones
8.8.3. Clinical Development
8.8.4. Product Profile
8.9. Travatan Z (travoprost ophthalmic solution) 0.004%: Alcon
8.9.1. Product Description
8.9.2. Regulatory Milestones
8.9.3. Clinical Development
8.9.4. Clinical Trials Information
8.9.5. Safety and Efficacy
8.9.6. Product Profile
8.10. Eybelis Ophthalmic Solution 0.002% (DE-117,Omidenepag isopropyl): Santen Pharmaceutical/Ube Industries
8.10.1. Product Description
8.10.2. Regulatory Milestones
8.10.3. Other Developmental Activities
8.10.4. Clinical Development
8.10.5. Clinical Trials Information
8.10.6. Safety and Efficacy
8.10.7. Product Profile
8.11. Vyzulta (BOL-303259-X): Bausch and Lomb
8.11.1. Product Description
8.11.2. Regulatory Milestones
8.11.3. Other Developmental Activities
8.11.4. Clinical Development
8.11.5. Clinical Trials Information
8.11.6. Safety and Efficacy
8.11.7. Product Profile
8.12. Rocklatan: Aerie Pharmaceuticals
8.12.1. Product Description
8.12.2. Regulatory Milestones
8.12.3. Other Developmental Activities
8.12.4. Clinical Development
8.12.5. Clinical Trials Information
8.12.6. Safety and Efficacy
8.12.7. Product Profile
8.13. Rhopressa: Aerie Pharmaceuticals
8.13.1. Product Description
8.13.2. Regulatory Milestones
8.13.3. Other Developmental Activities
8.13.4. Clinical Development
8.13.5. Clinical Trials Information
8.13.6. Safety and Efficacy
8.13.7. Product Profile
8.15. Zioptan (Tafluprost): Merck & Co
8.15.1. Product Description
8.15.2. Regulatory Milestones
8.15.3. Other Developmental Activities
8.15.4. Clinical Development
8.15.5. Clinical Trials Information
8.15.6. Safety and Efficacy
8.15.7. Product Profile
8.16. DuoTrav PQ (Travoprost/timolol): Novartis/ Alcon Research
8.16.1. Product Description
8.16.2. Regulatory Milestones
8.16.3. Other Developmental Activities
8.16.4. Clinical Development
8.16.5. Clinical Trials Information
8.16.6. Safety and Efficacy
8.16.7. Product Profile
8.17. Lumigan 0.01% (bimatoprost ophthalmic solution): Allergan
8.17.1. Product Description
8.17.2. Regulatory Milestones
8.17.3. Other Developmental Activities
8.17.4. Clinical Development
8.17.5. Clinical Trials Information
8.17.6. Safety and Efficacy
8.17.7. Product Profile
9. Emerging Therapies
9.1. Key Cross
9.2. PDP-716 (Brimonidine Tartrate Ophthalmic Suspension): Sun Pharma Advanced Research Company Limited (SPARC)
9.2.1. Product Description
9.2.2. Other Developmental Activities
9.2.3. Clinical Development
9.2.4. Clinical Trials Information
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.3. Brinzolamide Ophthalmic Solution 1%: Perrigo Company/ Bausch and Lomb
9.3.1. Product Description
9.3.2. Other Developmental Activities
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.5. Product Profile
9.4. DE-130A (Catioprost): Santen Pharmaceuticals
9.4.1. Product Description
9.4.2. Clinical Development
9.4.3. Clinical Trials Information
9.4.4. Product Profile
9.5. Sepetaprost (DE-126/ONO-9054): Santen Inc. /Ono Pharmaceutical
9.5.1. Product Description
9.5.2. Other Developmental Activities
9.5.3. Clinical Development
9.5.4. Clinical Trials Information
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. NCX-470: Nicox Opthalmics
9.6.1. Product Description
9.6.2. Other Developmental Activities
9.6.3. Clinical Development
9.6.4. Clinical Trials Information
9.6.5. Safety and Efficacy
9.6.6. Product Profile
9.7. Ripasudil Hydrochloride Hydrate/Brimonidine tartrate (K-232): Kowa Company/D. Western Therapeutics Institute
9.7.1. Product Description
9.7.2. Other Developmental Activities
9.7.3. Clinical Development
9.7.4. Clinical Trials Information
9.7.5. Product Profile
9.8. Bamosiran (SLY040012): Sylentis
9.8.1. Product Description
9.8.2. Other Developmental Activities
9.8.3. Clinical Development
9.8.4. Clinical Trials Information
9.8.5. Safety and Efficacy
9.8.6. Product Profile
9.9. Nyxol (Phentolamine Mesylate): Ocuphire Pharma
9.9.1. Product Description
9.9.2. Other Developmental Activities
9.9.3. Clinical Development
9.9.4. Clinical Trials Information
9.9.5. Safety and Efficacy
9.9.6. Product Profile
9.10. ENV515 (Travoprost XR): Envisia Therapeutics
9.10.1. Product Description
9.10.2. Other Developmental Activities
9.10.3. Clinical Development
9.10.4. Clinical Trials Information
9.10.5. Safety and Efficacy
9.10.6. Product Profile
9.11. POLAT-001: Peregrine Ophthalmic
9.11.1. Product Description
9.11.2. Other Developmental Activities
9.11.3. Clinical Development
9.11.4. Clinical Trials Information
9.11.5. Product Profile
9.12. TC-002 Latanoprost Ophthalmic solution: TearClear
9.12.1. Product Description
9.12.2. Other Developmental Activities
9.12.3. Clinical Development
9.12.4. Clinical Trials Information
9.12.5. Product Profile

10. Glaucoma: Seven Major Market Analysis
10.1. Key Findings
10.2. Market Methodology
10.3. Market Size of Glaucoma in the 7MM in USD Million (2019–2032)
10.4. Market Size of Glaucoma by Therapies in the 7MM
10.5. Market Outlook
10.6. Attribute Analysis
10.7. Potential of Current and Emerging therapy
10.8. Key Market Forecast Assumptions
10.9. United States Market Size
10.9.1. Total Market Size of Glaucoma in the United States
10.9.2. Market Size of Glaucoma by Therapies in the United States
10.10. EU-5 Market Size
10.10.1. Total Market size of Glaucoma in EU-5
10.10.2. Market Size of Glaucoma by Therapies in EU-5
10.11. Japan
10.11.1. Total Market size of Glaucoma in Japan
10.11.2. Market Size of Glaucoma by Therapies in Japan

11. KOL Views

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement

17. Appendix
17.1. Report Methodology
17.2. Bibliography

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight



List of Figures

Figure 1: Classification of Glaucoma
Figure 2: Classification of Open-Angle Glaucoma
Figure 3: Risk Factors Associated with POAG
Figure 4: Glaucoma classification and subtypes.
Figure 5: Symptoms of Open-Angle Glaucoma
Figure 6: Symptoms of Closed-angle Glaucoma
Figure 7 : Proposed pathways for normal secretion of myocilin into the aqueous humor and for secretion reduced by an MYOC mutation
Figure 8: Diagnosis of Glaucoma
Figure 9: Glaucoma Assessment (Optic Nerve)
Figure 10: Evaluation of a glaucoma suspect (open-angle glaucoma)
Figure 11: Treatment of primary open-angle glaucoma: Medical treatment
Figure 12: Treatment Algorithm for Open-Angle Glaucoma
Figure 13: Diagnostic and management algorithm for patient with JOAG
Figure 14: Treatment of Glaucoma
Figure 15: Total Diagnosed Prevalence of Glaucoma in the 7MM (2019–2032)
Figure 16: Total Diagnosed Prevalence of Glaucoma in the United States (2019–2032)
Figure 17: Type-specific Diagnosed Prevalence of Glaucoma in the US (2019–2032)
Figure 18: Type-specific Diagnosed Prevalence of OAG in the United States (2019–2032)
Figure 19: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States (2019–2032)
Figure 20: Gender-specific Diagnosed Prevalence of Glaucoma in the US (2019–2032)
Figure 21 Age-Specific Diagnosed Prevalence of Glaucoma in the United States (2019–2032)
Figure 22: Total Diagnosed Prevalence of Glaucoma in the EU-5 (2019–2032)
Figure 23: Type-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)
Figure 24: Type-specific Diagnosed Prevalence of OAG in EU-5 (2019–2032)
Figure 25: Type-specific Diagnosed Prevalence of secondary Open-Angle Glaucoma in EU-5 (2019–2032)
Figure 26: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)
Figure 27 Age-specific Diagnosed Prevalence of Glaucoma in EU-5 (2019–2032)
Figure 28: Total Diagnosed Prevalence of Glaucoma in Japan (2019–2032)
Figure 29: Type-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)
Figure 30: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2019–2032)
Figure 31: Type-specific Diagnosed Prevalence of Open-Angle Glaucoma in Japan (2019–2032)
Figure 32: Gender-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)
Figure 33: Age-specific Diagnosed Prevalence of Glaucoma in Japan (2019–2032)
Figure 34: Market Size of Glaucoma in the 7MM in USD Million (2019–2032)
Figure 35: Seven Major Market Size of Glaucoma by Therapies in the 7MM, in USD Million (2019–2032)
Figure 36: Market Size of Glaucoma in the US, USD Millions (2019–2032)
Figure 37: Market Size of Glaucoma by therapies in the United States, in USD Million (2019–2032)
Figure 38: Market Size of Glaucoma in EU-5, USD Million (2019–2032)
Figure 39: EU-5 Market Size of Glaucoma by Therapies in USD Million (2019–2032)
Figure 40: Market Size of Glaucoma in Japan, USD Million (2019–2032)
Figure 41:Japan Market Size of Glaucoma by Therapies in USD Million (2019–2032)
Figure 42: Market Drivers
Figure 43: Market Barriers
Figure 44: Unmet Needs

List of Tables

Table 1: Summary of Glaucoma Market, Epidemiology, and Key Events (2019–2032)
Table 2: Two Classes of Primary Open-Angle Glaucoma (POAG) Mutations
Table 3: Genes associated with the risk of POAG
Table 4 : Genes identified in linkage or association with PACG
Table 5: Clinical findings that define patients seen with Angle-Closure disease
Table 6: Differential Diagnosis for Glaucoma
Table 7: The definitions and levels of evidence to rate individual studies
Table 8: Recommendations for care are formed based on the body of the evidence. The body of evidence quality ratings are defined by GRADE
Table 9: Primary Open-Angle Glaucoma Preferred Practice Pattern guidelines
Table 10: Primary Closed-Angle Glaucoma Preferred Practice Pattern guidelines
Table 11: Initiating Open-angle Glaucoma Care – International Recommendations
Table 12: Medicines for Glaucoma Care: International Recommendations
Table 13: Initiating Closed-angle Care – International Recommendations
Table 14: Unstable Closed-angle Glaucoma – International Recommendations
Table 15: Level of evidence and recommendation in medical treatment of PACG
Table 16: Level of evidence and recommendation in treatment laser del PACG
Table 17: Level of evidence and recommendation in the surgical treatment of PACG
Table 18: Total Diagnosed Prevalence of Glaucoma in the 7MM,in ’00 (2019–2032)
Table 19: Total Diagnosed Prevalence of Glaucoma in the United State, in ?00 (2019–2032)
Table 20: Type-specific Diagnosed Prevalence of Glaucoma in the US, in ’00 (2019–2032)
Table 21: Type-specific Diagnosed Prevalence of OAG in the United States, in ?00 (2019–2032)
Table 22: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in the United States, in ’00 (2019–2032)
Table 23: Gender-specific Diagnosed Prevalence of Glaucoma in the US, in ’00 (2019–2032)
Table 24: Age-Specific Diagnosed Prevalence of Glaucoma in the United States, in ’00 (2019–2032)
Table 25: Total Diagnosed Prevalence of Glaucoma in EU-5, in ?00 (2019–2032)
Table 26: Type-specific Diagnosed Prevalence of Glaucoma in EU-5, in ’00 (2019–2032)
Table 27: Type-specific Diagnosed Prevalence of OAG in EU-5, in ?00 (2019–2032)
Table 28: Type-specific Diagnosed Prevalence of Secondary Open-Angle Glaucoma in EU-5, in ’00 (2019–2032)
Table 29: Gender-specific Diagnosed Prevalence of Glaucoma in EU-5, in ’00 (2019–2032)
Table 30: Age-Specific Diagnosed Prevalence of Glaucoma in EU-5, in ’00 (2019–2032)
Table 31: Total Diagnosed Prevalence of Glaucoma in Japan, in ?00 (2019–2032)
Table 32: Type-specific Diagnosed Prevalence of Glaucoma, in Japan in ’00 (2019–2032)
Table 33: Type-specific Diagnosed Prevalence of OAG in Japan, in ?00 (2019–2032)
Table 34: Type-specific Diagnosed Prevalence of Secondary OAG in Japan, in ?00 (2019–2032)
Table 35: Gender-specific Diagnosed Prevalence of Glaucoma in Japan, in ’00 (2019–2032)
Table 36: Age-Specific Diagnosed Prevalence of Glaucoma in Japan, in ’00 (2019–2032)
Table 37: Key cross competition- Marketed drugs
Table 38: Durysta (Bimatoprost SR), Clinical Trial Description, 2022
Table 39: Tapcom/DE-111(Tafluprost/ timolol maleate); Clinical Trial Description, 2022
Table 40: Glanatec, Clinical Trial Description, 2022
Table 41: Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, Clinical Trial Description, 2022
Table 42: Travatan Z (travoprost ophthalmic solution) 0.004%, Clinical Trial Description, 2022
Table 43: Eybelis ophthalmic solution (DE-117), Clinical Trial Description, 2022
Table 44: Vyzulta(BOL-303259-X), Clinical Trial Description, 2022
Table 45: Rocklatan(PG324, Netarsudil/Latanoprost 0.02%/0.005%), Clinical Trial Description, 2022
Table 46: Rhopressa(ART-1334), Clinical Trial Description, 2022
Table 47: Zioptan (Tafluprost), Clinical Trial Description, 2022
Table 48: DuoTrav, Clinical Trial Description, 2022
Table 49: Lumigan (Bimatoprost 0.01% Ophthalmic Solution) ,Clinical Trial Description, 2022
Table 50: Key-cross competition - emerging drugs
Table 51: PDP–716 (Brimonidine Tartrate Ophthalmic Suspension), Clinical Trial Description, 2022
Table 52: Brinzolamide Ophthalmic Suspension 1%, Clinical Trial Description, 2022
Table 53: DE-130A (Catioprost), Clinical Trial Description, 2022
Table 54: Sepetaprost (DE-126/ ONO-9054), Clinical Trial Description, 2022
Table 55: NCX 470, Clinical Trial Description, 2022
Table 56: K-232, Clinical Trial Description, 2022
Table 57: Bamosiran (SLY040012), Clinical Trial Description, 2022
Table 58: Nyxol (Phentolamine Mesylate), Clinical Trial Description, 2022
Table 59: ENV-515 (Travoprost), Clinical Trial Description, 2022
Table 60: POLAT-001, Clinical Trial Description, 2022
Table 61: TC-002(Latanoprost ophthalmic solution), Clinical Trial Description, 2022
Table 62: Market Size of Glaucoma in the 7MM in USD Million (2019–2032)
Table 63: Market Size of Glaucoma by therapies in the 7MM, in USD Million (2019–2032)
Table 64: Currently Prescribed Classes and their Side-Effects
Table 65: Key Market Forecast Assumptions for Vyzulta
Table 66: Key Market Forecast Assumptions for Rhopressa/Rhokiinsa
Table 67: Key Market Forecast Assumptions for Roclanda/Rocklatan
Table 68: Key Market Forecast Assumptions for Xelpros
Table 69: Key Market Forecast Assumptions for DURYSTA (bimatoprost implant)
Table 70: Key Market Forecast Assumptions for EYBELIS/Omidenepag isopropyl/DE-117
Table 71: Key Market Forecast Assumptions for PDP-716
Table 72: Key Market Forecast Assumptions for DE-130A
Table 73: Key Market Forecast Assumptions for Sepetaprost (DE-126/ONO-9054)
Table 74: Key Market Forecast Assumptions for NCX 470
Table 75: Key Market Forecast Assumptions for Nyxol
Table 76: Key Market Forecast Assumptions for K-232 (Ripasudil/Brimonidine)
Table 77: Market Size of Glaucoma in the United States in USD Million (2019–2032)
Table 78: Market Size of Glaucoma by therapies in the United States, in USD Million (2019–2032)
Table 79: Germany Market Size of Glaucoma in USD Million (2019–2032)
Table 80: Market Size of Glaucoma by therapies in EU-5 in USD Million (2019–2032)
Table 81: Japan Market Size of Glaucoma in USD Million (2019–2032)
Table 82:Market Size of Glaucoma by therapies in Japan, in USD Million (2019–2032)